Loading stock data…
AMPH
$21.88-0.08 (-0.36%)
Market ClosedLast close May 1
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amphastar Pharmaceuticals, Inc. in the Healthcare sector is trading at $21.88. The stock is currently 30% below its 52-week high of $31.26, remaining 12.8% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why AMPH maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.88
Potential Upside
106.9%
Whystock Fair Value$45.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$26.86+22.7%
Range$22.00 – $30.00
Fundamentals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$935.68M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.35
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.08%
Volume
Today's trading volume
300,350
Recent News
Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the best drug stocks to buy according to analysts. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was downgraded to Hold from Buy by Jefferies on April 20, with the firm bringing the price target on the stock down to $22 from $30. Despite what it calls an “inexpensive valuation”, the firm cited new […]
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
AMPH vs. RDY: Which Stock Is the Better Value Option?
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.7% in the afternoon session after Jefferies downgraded the stock to Hold from Buy and cut its price target.